Alnylam Pharmaceuticals (NASDAQ:ALNY) and Vir Biotechnology (NASDAQ:VIR) have expanded their collaboration to include RNAi therapeutics to potentially treat SARS-CoV-2 infection, the coronavirus causing the current outbreak, COVID-19.
Vir will lead development while Alnylam will retain an option for 50/50 participation.
Alnylam says it has designed and synthesized over 350 siRNAs targeting all available SARS-CoV and SARS-CoV-2 genomes.
The companies are also collaborating on a
treatment of chronic hepatitis B virus (HBV) infection called VIR-2218
(ALN-HBV02), currently in Phase 1/2 development.
Vir is up 15% premarket on modest volume.
https://seekingalpha.com/news/3548478-alnylam-and-vir-biotech-expand-partnership-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.